Guggenheim reiterates Uber stock rating citing growth and valuation

Guggenheim has reaffirmed its Buy rating and maintained a $275.00 price target on Revolution Medicines Inc. (RVMD) after a positive regulatory update from the European Medicines Agency (EMA). The stock has appreciated 281% over the past year, reaching $189.26. However, an InvestingPro analysis indicates the shares might be overvalued at their current level compared to their estimated Fair Value.

The EMA's Committee for Medicinal Products for Human Use has given a favorable opinion, recommending EU approval of Revolution's drug daraxonib, sold under the brand name Rasonque. This recommendation is based on the positive results from the Phase 3 RASolute 302 trial. Revolution Medicines has commenced the Marketing Authorization Application process in Europe, utilizing an expedited phased review method under the EMA's Cancer Medicines Pathfinder project.

The company anticipates a timely launch in Europe, with pricing, reimbursement, and market access negotiations conducted on a country-by-country basis following approval. In the U.S., a commercial launch is already in progress, with no obstacles from payors for on-label prescriptions. Additionally, off-label prescriptions have been rising since Rasonque was incorporated into the National Comprehensive Cancer Network (NCCN) treatment guidelines for non-small cell lung cancer at the 200 mg once-daily phase 2 dose.

For further details regarding Revolution Medicines' financial condition and growth prospects, investors can refer to the extensive Pro Research Report, exclusively accessible on InvestingPro, alongside an additional 11 ProTips. The company intends to present an update on its metastatic colorectal cancer portfolio development strategy during the fourth quarter, with the path to market in colorectal cancer contingent on combination data to be disclosed during the update.